Literature DB >> 29872890

[Hypothyroidism-when and how to treat?]

V F Koehler1, M Reincke1, C Spitzweg2.   

Abstract

The diagnosis of hypothyroidism is primarily based on clinical signs and symptoms as well as measurement of thyroid-stimulating hormone (TSH) concentration. Subclinical hypothyroidism is characterized by elevated TSH with normal serum free thyroxine (fT4) and triiodothyronine (fT3) levels, while in manifest hypothyroidism serum fT4 and fT3 levels are reduced. Common causes of primary hypothyroidism are autoimmune thyroiditis as well as therapeutic interventions, such as thyroid surgery or radioiodine therapy. Signs and symptoms of hypothyroidism include fatigue, bradycardia, constipation and cold intolerance. In subclinical hypothyroidism, symptoms may be absent. Initiation of levothyroxine (T4) therapy not only depends on the level of TSH elevation, but also on other factors, such as patient age, presence of pregnancy or comorbidities. Treatment of patients with subclinical hypothyroidism is still a controversial topic. In general, thyroid hormone replacement therapy in non-pregnant adults ≤ 70 years is clearly indicated if the TSH concentration is >10 mU/l. Standard of care for treatment of hypothyroidism is T4 monotherapy. The biochemical treatment goal for T4 replacement in primary hypothyroidism is a TSH level within the reference range (0.4-4.0 mU/l). In contrast, in secondary hypothyroidism, serum fT4 levels are the basis for adjusting thyroid hormone dosage. Inadequate replacement of T4 resulting in subclinical or even manifest hyperthyroidism should urgently be avoided. T4/liothyronine (T3) combination therapy is still a matter of debate and not recommended as standard therapy, but may be considered in patients with persistence of symptoms, despite optimal T4 treatment, based on expert opinion.

Entities:  

Keywords:  Hypothyroidism, subclinical; Thyroiditis, autoimmune; Thyrotropin; Thyroxine; Triiodothyronine

Mesh:

Substances:

Year:  2018        PMID: 29872890     DOI: 10.1007/s00108-018-0438-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  26 in total

1.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

2.  Regulatory role of triiodothyronine in the degradation of low density lipoprotein by cultured human skin fibroblasts.

Authors:  A Chait; E L Bierman; J J Albers
Journal:  J Clin Endocrinol Metab       Date:  1979-05       Impact factor: 5.958

3.  Age and gender substantially influence the relationship between thyroid status and the lipoprotein profile: results from a large cross-sectional study.

Authors:  Sara Tognini; Antonio Polini; Giuseppe Pasqualetti; Silvia Ursino; Nadia Caraccio; Marco Ferdeghini; Fabio Monzani
Journal:  Thyroid       Date:  2012-10-10       Impact factor: 6.568

4.  Thyroid status, cardiovascular risk, and mortality in older adults.

Authors:  Anne R Cappola; Linda P Fried; Alice M Arnold; Mark D Danese; Lewis H Kuller; Gregory L Burke; Russell P Tracy; Paul W Ladenson
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

5.  Subclinical hypothyroidism and the risk of coronary heart disease and mortality.

Authors:  Nicolas Rodondi; Wendy P J den Elzen; Douglas C Bauer; Anne R Cappola; Salman Razvi; John P Walsh; Bjørn O Asvold; Giorgio Iervasi; Misa Imaizumi; Tinh-Hai Collet; Alexandra Bremner; Patrick Maisonneuve; José A Sgarbi; Kay-Tee Khaw; Mark P J Vanderpump; Anne B Newman; Jacques Cornuz; Jayne A Franklyn; Rudi G J Westendorp; Eric Vittinghoff; Jacobijn Gussekloo
Journal:  JAMA       Date:  2010-09-22       Impact factor: 56.272

6.  Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial.

Authors:  Ponnusamy Saravanan; Dawn J Simmons; Rosemary Greenwood; Tim J Peters; Colin M Dayan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-07       Impact factor: 5.958

7.  Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects.

Authors:  Robin P Peeters; Hans van Toor; Willem Klootwijk; Yolanda B de Rijke; George G J M Kuiper; Andre G Uitterlinden; Theo J Visser
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

Review 8.  Maternal hypothyroxinemia and effects on cognitive functioning in childhood: how and why?

Authors:  Jens Henrichs; Akhgar Ghassabian; Robin P Peeters; Henning Tiemeier
Journal:  Clin Endocrinol (Oxf)       Date:  2013-05-21       Impact factor: 3.478

Review 9.  Mechanisms in endocrinology: Heart failure and thyroid dysfunction.

Authors:  Bernadette Biondi
Journal:  Eur J Endocrinol       Date:  2012-09-06       Impact factor: 6.664

10.  Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine.

Authors:  Joao Pedro Werneck de Castro; Tatiana L Fonseca; Cintia B Ueta; Elizabeth A McAninch; Sherine Abdalla; Gabor Wittmann; Ronald M Lechan; Balazs Gereben; Antonio C Bianco
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

View more
  1 in total

1.  Effects of Shuganjianpihuatanxingqi decoction on mild subclinical hypothyroidism: A SPIRIT compliant randomized controlled trial study protocol.

Authors:  Litao Bai; Jing Zhao; Jialiang Gao; Fei Li; Fan Wei; Jun Li; Yao Xiao; Xu Han; Yaoli Wang; Danwei Wang; Fangying Wu; Junping Wei
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.